264 filings
8-K
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
S-3
LRMR
Larimar Therapeutics Inc
Shelf registration
9 May 24
4:50pm
10-Q
2024 Q1
LRMR
Larimar Therapeutics Inc
Quarterly report
9 May 24
4:11pm
8-K
LRMR
Larimar Therapeutics Inc
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
ARS
2023 FY
LRMR
Larimar Therapeutics Inc
29 Apr 24
Annual report to shareholders
4:04pm
PRE 14A
8z05vfcp2x273
12 Apr 24
Preliminary proxy
6:06am
S-8
mtxq9cref71bv
14 Mar 24
Registration of securities for employees
5:07pm
S-8
jaxyrgm5t xx
14 Mar 24
Registration of securities for employees
5:07pm
8-K
83kdbj zy
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
8-K
824 nanf2nj
11 Mar 24
Other Events
4:09pm
8-K
o5c6my5i0
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
awx8q kl4d96v5f
14 Feb 24
Prospectus supplement for primary offering
5:08pm
8-K
7di0 tkgpzq6o2qqoo
14 Feb 24
Termination of a Material Definitive Agreement
6:06am
424B5
hcvovw6f257 tfgrgth
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
ag05xl3vr
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
0d35fou22kg11fdt1o
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
eaelee 951
3 Oct 23
Departure of Directors or Certain Officers
4:31pm